An official website of the United States government Here’s how you know

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

In this section: Postmarket Drug Safety Information for Patients and Providers

Ampyra (dalfampridine) Information

Ampyra (dalfampridine) was approved on January 22, 2010, to improve walking in patients with multiple sclerosis (MS).

To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program using the information at the bottom of this page.

Related Information

FDA Drug Safety Communication: Seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine)

Approval History and Labeling from Drugs@FDA

Ampyra (dalfampridine) Labeling and Approval History

Top